How High Will BioCryst Go?

stock price forecast The 12 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 13.50, with a high estimate of 30.00 and a low estimate of 11.00. The median estimate represents a +44.23% increase from the last price of 9.36.

Is BioCryst Pharmaceuticals stock a good buy?

BioCryst Pharmaceuticals has received a consensus rating of Buy The company’s average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.

Why is BioCryst stock dropping?

BioCryst Pharmaceuticals (NASDAQ:BCRX) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results.

Will BCRX go back up?

Based on our forecasts, a long-term increase is expected , the “BCRX” stock price prognosis for 2027-06-25 is 24.509 USD. With a 5-year investment, the revenue is expected to be around +127.99%. Your current $100 investment may be up to $227.99 in 2027. Get It Now!.

Will BCRX go up?

Based on 11 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $17.00 with a high forecast of $30.00 and a low forecast of $12.00 The average price target represents a 60.68% change from the last price of $10.58.

Is BCRX undervalued?

Slightly overvalued with limited growth.

Will BXRX stock go up?

Baudax Bio Inc (NASDAQ:BXRX) The 1 analysts offering 12-month price forecasts for Baudax Bio Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00 The median estimate represents a +980.79% increase from the last price of 0.74.

When did BCRX go public?

BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994 The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.

Should I sell BXRX stock?

The consensus among 1 Wall Street analyst covering (NASDAQ: BXRX) stock is to Strong Buy BXRX stock.

Should I invest in BXRX?

The financial health and growth prospects of BXRX, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.

Is Baudax bio stock a buy?

There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Baudax Bio stock.

What does BioCryst make?

BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

Where is BioCryst?

BioCryst’s US headquarters is located in Durham, North Carolina , our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.


You May Also Like